Oxford Gene Technology (OGT) released a new microarray designed to improve the accuracy and efficiency of cancer research. The CytoSure Cancer +SNP array (4x180k) combines long oligo array comparative genomic hybridisation (aCGH) probes with fully validated single nucleotide polymorphism (SNP) content, providing the detection of both copy number variations (CNVs) and loss of heterozygosity (LOH) on a single chip. The array has been optimized in collaboration with Professor Jacqueline Schoumans from the Lausanne University Hospital in Switzerland, an expert in both aCGH and cancer genomics. Unique to the proprietary CytoSure Cancer +SNP array, any reference sample can be used for analysis without changes to the standard aCGH protocol and, thanks to novel SNP probe chemistry, no restriction digest is required. The capacity to use matched samples is a particular advantage for research into genetic aberrations in cancer, enabling any constitutional abnormalities to be filtered out. The 60-mer oligonucleotide probes utilized in the array provide a high signal-to-noise ratio and highly sensitive detection; this makes them ideal for research into complex malignant tissues. OGT’s CytoSure Interpret Software is used for data analysis, including updated features, such as the B-allele frequency plot, that have been optimized for the identification of biologically relevant genomic variants in tumor samples.
Oxford Gene Technology (OGT), +44-0-1865-856800, www.ogt.com/cancer